MISE & Agrave; DAY
WASHINGTON | U.S. health officials further lowered the age at which a booster dose of Pfizer's COVID vaccine can be received on Thursday, allowing it in adolescents aged 16 and 17. & nbsp;
The announcement comes the day after data released by the company showing that a booster dose is expected to be crucial in combating the Omicron variant.
The emergency authorization request had been filed by Pfizer-BioNTech less than two weeks ago.
This dose can be received at least six months after the first series of injections, announced the American Medicines Agency (FDA).
Pfizer's vaccine is the only one authorized in the United States under the age of 18, from 5 years old for the first two shots.
As the holiday season approaches and “the Delta and Omicron variants continue to spread, vaccination remains our best protection against COVID-19,” Acting FDA Chief Janet Woodcock said in a statement./p>
“The effectiveness of the vaccine against COVID-19 decreases after the second dose, for all adults and for the group of 16 and 17 years”, also justified Peter Marks, scientific director within the FDA.
Adolescents are generally much less likely than older adults to develop a severe case of the disease.
Among them, boys in particular are more prone to an increased risk of myocarditis, an inflammation of the heart muscle, after vaccination with Pfizer or Moderna. These cases remain rare, but in recent months had led the authorities to adopt a cautious stance concerning a recall among the youngest.
However, they estimated Thursday that the balance between the benefits and the risks was clearly tilted in favor of vaccination.
The Centers for Disease Prevention and Control (CDC) must quickly endorse this authorization.